MedTrace Logo

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

NCT04535752 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-08-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmakokinetics and pharmacodynamics of single and repeated doses of ANX009

Conditions

  • Safety and Tolerability in Healthy Volunteers

Interventions

DRUG

ANX009

Single or multiple ascending dose

DRUG

Placebo

Single or multiple ascending dose

Sponsors & Collaborators

  • Nucleus Network Ltd

    collaborator OTHER

  • Annexon, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Humphriss, MBA · Annexon Director, Global Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2021-06-26
Completion
2021-06-26

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535752 on ClinicalTrials.gov